Company intelligence / Profile preview

BioVex Group, Inc.

Woburn, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~66
Development stage: Phase 2

Overview

BioVex developed OncoVEX(GM-CSF), an investigational oncolytic vaccine that reached Phase 3 clinical development for treating melanoma and head and neck cancer. The company was acquired by Amgen in March 2011, and its lead product (later known as T-Vec or talimogene laherparepvec) received FDA approval on October 27, 2015.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Biologicsoncolytic viruses
Industry: Biotech

Drug pipeline

4 assets

OncoVEX GM-CSF

Phase 2

Indications: Head and neck cancer, Melanoma, Pancreatic cancer, Colorectal cancer liver metastases

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioVex Group, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioVex Group, Inc..

Explore the full profile